Cancer and COVID-19: Resources for Patients and Survivors

Preparing for Your Next Clinic Visit

Dr. Marshall explains procedures MedStar and Georgetown have instituted to ensure your safety while you receive the best care possible

View Q&A with Dr. Marshall

Current Clinical Trials

Search our current GI clinical trials offered through the MedStar Georgetown Cancer Institute

View Clinical Trials

New Colon Cancer Concerns

Dr. Marshall talks with Today Show about why colon cancer is on the rise in young patients

View Today Show Segment with Dr. Marshall

2020 Ruesch Center Classic Golf Tournament

Learn more about this year’s event on Monday, August 10, 2020

More information

Dr. John L. Marshall addresses some of the questions he and his Georgetown Lombardi colleagues have been hearing most often from current cancer patients and survivors. Learn More

Gastrointestinal (GI) Cancers are the most common and most fatal of all cancers. The Ruesch Center will re-focus national efforts on curing this deadly set of diseases.

Indivumed Global Alliance to Broaden Access to Multi-Omics Algorithms, Precision Medicine Education

May 4th, 2020

Germany-based Indivumed is enlisting the help of cancer centers and research institutions around the world to help expand its omics database and make it a key resource for unraveling the complexities of cancer biology and advancing new precision oncology drugs. Indivumed last month launched the Oncology Alliance for Individualized Medicine (Onco AI-Med), which is a partnership between leading cancer clinics and research institutions selected based on their research activities and expertise in molecularly informed cancer care. Currently, the collaboration includes over 30 partners from 11 countries, though Indivumed plans to add new sites to the alliance continuously.

Colorectal cancer care in the age of coronavirus: strategies to reduce risk and maintain benefit

April 16th, 2020

We are in unprecedented times requiring us to approach our medical obligations in unprecedented ways. Cancer care is not elective and therefore must be maintained throughout the COVID-19 pandemic. However, we recognize that there is early evidence based on small studies from China and Italy that cancer patients are at increased risk of severe illness if they are to develop a COVID-19 infection and there is even some evidence to suggest that healthcare providers are at increased risk, possibly due to exposure to larger viral loads and repeated exposure…

Sign Up to receive all Ruesch updates directly in your Inbox

We will deliver our quarterly newsletter, monthly updates and other announcements to your Inbox with information on upcoming special events, current clinical trials and cutting edge research and trends in the GI cancer field.